Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

ETV6–FLT3 fusion gene-positive, eosinophilia-associated myeloproliferative neoplasm successfully treated with sorafenib and allogeneic stem cell transplant

Leukemia volume 28, pages 2090–2092 (2014)Cite this article

Subjects

Myeloid/lymphoid neoplasms associated with eosinophilia (MLN-eos) and rearrangement of PDGFRA, PDGFRB or FGFR1 are established types of hematologic neoplasms according to the most recent World Health Organization (WHO) classification. Such classification has therapeutic implications because these MLN-eos are driven by chimeric oncoproteins, including targetable receptor or non-receptor tyrosine kinases (TKs).1

ETS variant gene 6 (ETV6) maps to chromosome 12p13 and encodes a nuclear protein crucial for hematopoietic regulation. ETV6 is frequently rearranged in hematologic malignancies and can participate in fusion with genes coding for TKs, often resulting in constitutive activation of the latter.2 In particular, ETV6 has been found fused to the Fms-like tyrosine kinase 3 (FLT3) gene in several cases of MLN-eos as a result of the t(12;13)(p13;q12) translocation.3, 4, 5 We report a case of indolent ETV6–FLT3-positive MLN-eos successfully treated with the FLT3 inhibitor sorafenib followed by allogeneic stem cell transplantation (SCT).

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Bain B, Gilliland D, Horny H-P, Vardiman J . Myeloid and Lymphoid Neoplasms with Eosinophilia and Abnormalities of PDGFRA, PDGFRB, or FGFR1. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, France, 2008; pp 68–73.

    Google Scholar 

  2. De Braekeleer E, Douet-Guilbert N, Morel F, Le Bris MJ, Basinko A, De Braekeleer M . ETV6 fusion genes in hematological malignancies: a review. Leuk Res 2012; 36: 945–961.

    Article  CAS  PubMed  Google Scholar 

  3. Vu HA, Xinh PT, Masuda M, Motoji T, Toyoda A, Sakaki Y et al. FLT3 is fused to ETV6 in a myeloproliferative disorder with hypereosinophilia and a t(12;13)(p13;q12) translocation. Leukemia 2006; 20: 1414–1421.

    Article  CAS  PubMed  Google Scholar 

  4. Walz C, Erben P, Ritter M, Bloor A, Metzgeroth G, Telford N et al. Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3. Blood 2011; 118: 2239–2242.

    Article  CAS  PubMed  Google Scholar 

  5. Chonabayashi K, Hishizawa M, Matsui M, Kondo T, Ohno T, Ishikawa T et al. Successful allogeneic stem cell transplantation with long-term remission of ETV6/FLT3-positive myeloid/lymphoid neoplasm with eosinophilia. Ann Hematol 2013; 93: 535–537.

    Article  PubMed  Google Scholar 

  6. Jaso JM, Yin CC, Lu VW, Zhao M, Abruzzo LV, You MJ et al. B acute lymphoblastic leukemia with t(14;19)(q32;p13.1) involving IGH/EPOR: a clinically aggressive subset of disease. Mod Pathol 2013.

  7. Matthews W, Jordan CT, Wiegand GW, Pardoll D, Lemischka lR . A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. Cell 1991; 65: 1143–1152.

    Article  CAS  PubMed  Google Scholar 

  8. Rosnet O, Mattei M-G, Marchetto S, Birnbaum D . Isolation and chromosomal localization of a novel FMS-like tyrosine kinase gene. Genomics 1991; 9: 380–385.

    Article  CAS  PubMed  Google Scholar 

  9. Stirewalt DL, Radich JP . The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer 2003; 3: 650–665.

    Article  CAS  PubMed  Google Scholar 

  10. Vu HA, Xinh PT, Kano Y, Tokunaga K, Sato Y . The juxtamembrane domain in ETV6/FLT3 is critical for PIM-1 up-regulation and cell proliferation. Biochem Biophys Res Commun. 2009; 383: 308–313.

    Article  CAS  PubMed  Google Scholar 

  11. Chonabayashi K, Hishizawa M, Kawamata S, Nagai Y, Ohno T, Ishikawa T et al. Direct binding of Grb2 has an important role in the development of myeloproliferative disease induced by ETV6/FLT3. Leukemia 2013; 27: 1433–1436.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    L Falchi, K J Newberry, L M Lyle & S Verstovsek

  2. Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    M Mehrotra, G Lu, K P Patel & R Luthra

  3. Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    U Popat

Authors
  1. L Falchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Mehrotra
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K J Newberry
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L M Lyle
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. K P Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R Luthra
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. U Popat
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. S Verstovsek
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S Verstovsek.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Author contributions

LF conceived and designed the work that led to the submission, acquired and interpreted the data, and drafted and approved the final manuscript; MM GL, KPP, RL, UP and LML acquired data and revised and approved the final manuscript; treated the patient and revised and approved the final manuscript; SV conceived and designed the work that led to the submission, interpreted the data, revised and approved the final manuscript.

Supplementary Information accompanies this paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Falchi, L., Mehrotra, M., Newberry, K. et al. ETV6–FLT3 fusion gene-positive, eosinophilia-associated myeloproliferative neoplasm successfully treated with sorafenib and allogeneic stem cell transplant. Leukemia 28, 2090–2092 (2014). https://doi.org/10.1038/leu.2014.168

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2014.168

This article is cited by

Search

Advanced search

Quick links